In-Cell Test for Papillomavirus

The new test is compatible with conventional Pap tests, liquid-based cytology specimens, and a new test under development that uses biomolecular marker probes. Based on technology licensed from Invirion (Frankfort, MI, USA), the test is the product of Ampersand Medical Corp. (Chicago, IL, USA) and is a companion product to Ampersand's InPath System.

The InPath System, based on biomolecular markers and fluorescence, represents a revolutionary approach to cervical cancer screening, says Ampersand. The system includes the use of multiple protein-based probes and stains used in combinations that are able to detect low-grade as well as high-grade dysplasia and cancer. InPath together with the new HPV test will offer a complete two-in-one, point-of-care screening system for cervical cancer.

"The combination of this HPV test and our InPath System is designed to keep cells intact, unlike other HPV screening options,” notes Peter Gombrich, chairman and CEO of Ampersand Medical. "This will enable pathologists and clinicians to determine cause-and-effect relationships between HPV and the presence of other diseases and symptoms, such as cervical cancer.”



Related Links:
Ampersand Medical